Company intelligence / Profile preview

Libra Corporation

San Diego, California, United Statessec.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Libra Therapeutics has developed a pipeline of novel small molecule therapeutics targeting key mechanisms underlying neurodegenerative diseases. Their lead program targets TRPML1 to enhance autophagy and lysosomal function. As of mid/late 2024, all programs remain preclinical with the first-in-human trial planned for their TRPML1-targeting candidate in early/mid–2025. No clinical results have been reported yet.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Axxam S.p.A. – foundational research partner providing proprietary chemical matter and assaysMultiple international CROs including Axxam handle R&D operations

Beyond the preview

Go deeper on Libra Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libra Corporation.

Explore the full profile